Aneel Paulus

12PUBLICATIONS
78CO-AUTHORS
Molecular targetsImmunogenetics (incl. genetic immunology)Biomolecular modelling and designCancer therapy (excl. chemotherapy and radiation therapy)Major global burdens of disease
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Apr 19, 2023
Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial.

Sikander Ailawadhi, Zi Chen, Bo Huang

|Jan 21, 2023
AT-101 Enhances the Antitumor Activity of Lenalidomide in Patients with Multiple Myeloma.

Sikander Ailawadhi, Ricardo D Parrondo, Navnita Dutta

|Dec 19, 2022
Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies.

Patrizia Mondello, Jonas Paludo, Joseph P Novak

|Sep 01, 2022
Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy.

Jing Deng, Aneel Paulus, Douglas D Fang

|Aug 17, 2022
CD38 as a multifaceted immunotherapeutic target in CLL.

Aneel Paulus, Fabio Malavasi, Asher Chanan-Khan

|Jul 27, 2022
Updates in the Use of BCL-2-Family Small Molecule Inhibitors for the Treatment of Relapsed/Refractory Multiple Myeloma.

Ricardo D Parrondo, Aneel Paulus, Sikander Ailawadhi

Pageof 2

Frequent Collaborators

7 joint publications

Sikander Ailawadhi

3 joint publications

Asher Chanan-Khan

3 joint publications

Jithma P Abeykoon

3 joint publications

Morie A Gertz